Video

Dr. Castle on Adjuvant Versus Early Salvage Therapy in Prostate Cancer

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.

Erik P. Castle, MD, professor of urology, Mayo Clinic, discusses the use of adjuvant versus early salvage therapy in patients with prostate cancer, citing his own preference for early salvage therapy.

Though there are data that demonstrate a survival benefit in adjuvant radiotherapy in post-prostatectomy patients with high-risk features such as stage III disease, positive margins, and positive lymph nodes, Castle prefers to observe his patients and give early salvage if necessary.

There are data that have yet to be fully analyzed in ongoing and accruing clinical trials comparing early salvage to adjuvant therapy. Many patients with high-risk features were followed until they were symptomatic in the open prostatectomy series. A large percentage of patients will not recur and won’t be at risk of dying, even though they have some of these high-risk features.

Though there is a role for adjuvant therapy, especially in patients who have a high risk for recurrence and young patients who are going to need trimodality therapy, Castle advocates monitoring patients very closely in a very tight schedule of prostate-specific antigen (PSA) testing, utilizing their time to recurrence, and their PSA kinetics to determine how aggressive to be with radiation.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma
Video

Expert Perspectives on Applying Recent Evidence to Practice in the Management of Newly Diagnosed Multiple Myeloma

Jun 19th 2025 - Jul 25th 2025

online-activity
Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies
Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Jun 18th 2025 - Jun 19th 2026

online-activity
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity